论文部分内容阅读
背景:研究显示沙利度胺及其类似物具有免疫调节、抗血管生成、抗炎等多方面的作用,其对多发性骨髓瘤和一些实体瘤的抗肿瘤作用与其免疫调节活性以及抗血管生成、抗增殖和促凋亡特性有关。目的:观察沙利度胺对人胰腺癌细胞细胞动力学和血管内皮生长因子(VEGF)表达的影响,探讨其用于胰腺癌临床辅助治疗的可能性。方法:以沙利度胺干预人胰腺癌细胞株Patu-8988 48 h,MTT实验检测细胞增殖,流式细胞术检测细胞周期和细胞凋亡,RT-PCR检测VEGFmRNA表达。结果:经不同浓度沙利度胺干预的Patu-8988细胞,生长抑制率、G0/G1期细胞比例和细胞凋亡率均显著高于溶剂对照组(P<0.05),VEGF异构体VEGF121、VEGF165 mRNA表达显著低于溶剂对照组(P<0.05)。结论:沙利度胺能从多方面对胰腺癌生长产生抑制作用,包括直接抑制癌细胞增殖、诱导细胞周期G0/G1期阻滞和早期凋亡,以及通过抑制VEGF转录而抑制肿瘤血管发生。
BACKGROUND: Studies have shown thalidomide and its analogues have immunomodulatory, anti-angiogenic and anti-inflammatory effects in many aspects. Their antitumor effects on multiple myeloma and some solid tumors are related to their immunomodulatory activity and anti-angiogenesis , Anti-proliferative and pro-apoptotic properties. Objective: To observe the effect of thalidomide on the cell kinetics and the expression of vascular endothelial growth factor (VEGF) in human pancreatic cancer cells, and to explore its possibility of clinical adjuvant therapy for pancreatic cancer. Methods: Human pancreatic cancer cell line Patu-8988 was treated with thalidomide for 48 h. Cell proliferation was detected by MTT assay. Cell cycle and apoptosis were detected by flow cytometry. VEGF mRNA expression was detected by RT-PCR. Results: Patu-8988 cells treated with different concentrations of thalidomide had significantly higher growth inhibition rate, cell ratio at G0 / G1 phase and apoptosis rate than those of the solvent control group (P <0.05). VEGF isoforms VEGF121, VEGF165 mRNA expression was significantly lower than the solvent control group (P <0.05). CONCLUSIONS: Thalidomide can inhibit the growth of pancreatic cancer in many ways, including directly inhibiting the proliferation of cancer cells, inducing cell cycle G0 / G1 arrest and early apoptosis, and inhibiting tumor angiogenesis by inhibiting VEGF transcription.